The mycophenolate mofetil treatment utility for diffuse proliferative lupus nephritis class IV (WHO) in patients without control disease activity.

被引：0
|
作者：
Pérez, CM [1 ]
Gonzalez, SL [1 ]
Camargo, CA [1 ]
Hernandez, VR [1 ]
Canul, NE [1 ]
Fernandez, AG [1 ]
Ake, UM [1 ]
Medina, RF [1 ]
Fraga, MA [1 ]
机构：
[1] Ctr Med Nacl Siglo XXI, IMSS, Mexico City, DF, Mexico
来源：
JOURNAL OF RHEUMATOLOGY | 2006年 / 33卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：420 / 420
页数：1
相关论文
共 50 条
  • [31] Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?
    Eid M. El-Shafey
    Said H. Abdou
    Mohamed M. Shareef
    [J]. Clinical and Experimental Nephrology, 2010, 14 : 214 - 221
  • [32] Cost-Utility Analysis of Mycophenolate Mofetil versus Azathioprine Based Regimens for Maintenance Therapy of Proliferative Lupus Nephritis
    Nee, Robert
    Rivera, Ian
    Little, Dustin J.
    Yuan, Christina M.
    Abbott, Kevin C.
    [J]. INTERNATIONAL JOURNAL OF NEPHROLOGY, 2015, 2015
  • [33] Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?
    El-Shafey, Eid M.
    Abdou, Said H.
    Shareef, Mohamed M.
    [J]. CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2010, 14 (03) : 214 - 221
  • [34] Differences between class IV diffuse segmental (DS) and diffuse global (DG) proliferative lupus nephritis.
    Hill, PS
    Delahousse, M
    Nochy, D
    Bariety, J
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 379A - 379A
  • [35] Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis
    Smith, E. M. D.
    Al-Abadi, E.
    Armon, K.
    Bailey, K.
    Ciurtin, C.
    Davidson, J.
    Gardner-Medwin, J.
    Haslam, K.
    Hawley, D.
    Leahy, A.
    Leone, V.
    McErlane, F.
    Mewar, D.
    Modgil, G.
    Moots, R.
    Pilkington, C.
    Ramanan, A.
    Rangaraj, S.
    Riley, P.
    Sridhar, A.
    Wilkinson, N.
    Beresford, M. W.
    Hedrich, C. M.
    [J]. LUPUS, 2019, 28 (05) : 613 - 620
  • [36] Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study
    Onishi, Akira
    Sugiyama, Daisuke
    Tsuji, Go
    Nakazawa, Takashi
    Kogata, Yoshinori
    Tsuda, Kosaku
    Naka, Ikuko
    Nishimura, Keisuke
    Misaki, Kenta
    Kurimoto, Chiyo
    Hayashi, Hiroki
    Kageyama, Goichi
    Saegusa, Jun
    Sugimoto, Takeshi
    Kawano, Seiji
    Kumagai, Shunichi
    Morinobu, Akio
    [J]. MODERN RHEUMATOLOGY, 2013, 23 (01) : 89 - 96
  • [37] Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial
    Kamanamool, N.
    Ingsathit, A.
    Rattanasiri, S.
    Ngamjanyaporn, P.
    Kasitanont, N.
    Chawanasuntorapoj, R.
    Pichaiwong, W.
    Anutrakulchai, S.
    Sangthawan, P.
    Ophascharoensuk, V.
    Avihingsanon, Y.
    Sumethkul, V.
    [J]. LUPUS, 2018, 27 (04) : 647 - 656
  • [38] Mycophenolate mofetil in the treatment of lupus nephritis, in patients with failure, intolerance or relapses after treatment with steroids and cyclophosphamide
    Suria, S.
    Checa, A. D.
    [J]. NEFROLOGIA, 2007, 27 (04): : 459 - 465
  • [39] Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide
    Wang, J.
    Hu, W.
    Xie, H.
    Zhang, H.
    Chen, H.
    Zeng, C.
    Liu, Z.
    Li, L.
    [J]. LUPUS, 2007, 16 (09) : 707 - 712
  • [40] Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil
    Yap, D. Y. H.
    Yung, S.
    Ma, M. K. M.
    Mok, M. M. Y.
    Kwan, L. P. Y.
    Chan, G. C. W.
    Chan, T. M.
    [J]. LUPUS, 2014, 23 (07) : 678 - 683
12345